Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Aug;17(8):1195-201.
doi: 10.1101/gr.6468307. Epub 2007 Jun 28.

Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance

Chunlin Wang  1 , Yumi Mitsuya, Baback Gharizadeh, Mostafa Ronaghi, Robert W Shafer
Affiliations

Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance

Chunlin Wang et al. Genome Res. 2007 Aug.

Abstract

The detection of mutant spectra within a population of microorganisms is critical for the management of drug-resistant infections. We performed ultra-deep pyrosequencing to detect minor sequence variants in HIV-1 protease and reverse transcriptase (RT) genes from clinical plasma samples. We estimated empirical error rates from four HIV-1 plasmid clones and used them to develop a statistical approach to distinguish authentic minor variants from sequencing errors in eight clinical samples. Ultra-deep pyrosequencing detected an average of 58 variants per sample compared with an average of eight variants per sample detected by conventional direct-PCR dideoxynucleotide sequencing. In the clinical sample with the largest number of minor sequence variants, all 60 variants present in > or =3% of genomes and 20 of 35 variants present in <3% of genomes were confirmed by limiting dilution sequencing. With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Relationship between the number of required ultra-deep pyrosequencing reads per position (Required coverage) and the detection limit of the frequency of a minority sequence variant (Detection threshold). The excess number of reads required to detect minor variants is a result of the Poisson model for handling potential sequencing errors. For example, ∼400 (rather than 100) reads are required to detect a minor variant present at about a 1% level in a non-homopolymeric region. Because homopolymeric regions are more likely to contain sequencing errors, higher numbers of reads are required to obtain similar sensitivities in these regions.
Figure 2.
Figure 2.
Sequence variants detected by ultra-deep pyrosequencing of eight clinical plasma samples including seven samples from antiretroviral-experienced patients (F56272, V10606, V11909, V47683, V63557, V65472, V9878) and one sample from an untreated patient (92_2664). Sequence variants were defined as differences from the consensus population-based sequence. The X-axis represents all 99 protease codon positions followed by the first 240 reverse transcriptase codon positions. Positions are demarcated at intervals of 20 codons. The Y-axis shows the frequency of each minor variant observed by ultra-deep pyrosequencing. Synonymous minor variants are shown in gray; non-synonymous variants are shown in red. The presence of more than one variant at the same position is indicated by superimposing variants of lower frequency onto variants with higher frequency. Drug-resistance mutations detected only by ultra-deep pyrosequencing are indicated with arrows. A horizontal line separates minor variants present at above and below a frequency of 20%. As noted in the text, 55 of 72 variants present in >20% of GS20 reads, but only nine of 392 variants present in <20% of GS20, were detected by conventional Sanger sequencing.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cai F., Chen H., Hicks C.B., Bartlett J.A., Zhu J., Gao F., Chen H., Hicks C.B., Bartlett J.A., Zhu J., Gao F., Hicks C.B., Bartlett J.A., Zhu J., Gao F., Bartlett J.A., Zhu J., Gao F., Zhu J., Gao F., Gao F. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat. Methods. 2007;4:123–125. - PubMed
    1. Coffin J.M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483–489. - PubMed
    1. Edelstein R.E., Nickerson D.A., Tobe V.O., Manns-Arcuino L.A., Frenkel L.M., Nickerson D.A., Tobe V.O., Manns-Arcuino L.A., Frenkel L.M., Tobe V.O., Manns-Arcuino L.A., Frenkel L.M., Manns-Arcuino L.A., Frenkel L.M., Frenkel L.M. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J. Clin. Microbiol. 1998;36:569–572. - PMC - PubMed
    1. Ellis G.M., Mahalanabis M., Beck I.A., Pepper G., Wright A., Hamilton S., Holte S., Naugler W.E., Pawluk D.M., Li C.C., Mahalanabis M., Beck I.A., Pepper G., Wright A., Hamilton S., Holte S., Naugler W.E., Pawluk D.M., Li C.C., Beck I.A., Pepper G., Wright A., Hamilton S., Holte S., Naugler W.E., Pawluk D.M., Li C.C., Pepper G., Wright A., Hamilton S., Holte S., Naugler W.E., Pawluk D.M., Li C.C., Wright A., Hamilton S., Holte S., Naugler W.E., Pawluk D.M., Li C.C., Hamilton S., Holte S., Naugler W.E., Pawluk D.M., Li C.C., Holte S., Naugler W.E., Pawluk D.M., Li C.C., Naugler W.E., Pawluk D.M., Li C.C., Pawluk D.M., Li C.C., Li C.C., et al. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J. Clin. Microbiol. 2004;42:3670–3674. - PMC - PubMed
    1. Flys T., Nissley D.V., Claasen C.W., Jones D., Shi C., Guay L.A., Musoke P., Mmiro F., Strathern J.N., Jackson J.B., Nissley D.V., Claasen C.W., Jones D., Shi C., Guay L.A., Musoke P., Mmiro F., Strathern J.N., Jackson J.B., Claasen C.W., Jones D., Shi C., Guay L.A., Musoke P., Mmiro F., Strathern J.N., Jackson J.B., Jones D., Shi C., Guay L.A., Musoke P., Mmiro F., Strathern J.N., Jackson J.B., Shi C., Guay L.A., Musoke P., Mmiro F., Strathern J.N., Jackson J.B., Guay L.A., Musoke P., Mmiro F., Strathern J.N., Jackson J.B., Musoke P., Mmiro F., Strathern J.N., Jackson J.B., Mmiro F., Strathern J.N., Jackson J.B., Strathern J.N., Jackson J.B., Jackson J.B., et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J. Infect. Dis. 2005;192:24–29. - PubMed

Publication types